Proton Therapy for Chordoma and Chondrosarcoma

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Abramson Cancer Center at Penn Medicine

No Placebo Group

Approved in 4 jurisdictions

Trial Summary

What is the purpose of this trial?The objectives of this study are 1) To evaluate the feasibility and acute side effects of proton therapy for chordomas and chondrosarcomas and 2) To evaluate clinical outcomes and long term side effects of proton beam radiation for treatment of chordomas and chondrosarcomas.

Eligibility Criteria

This trial is for adults (18+) with confirmed chordoma or chondrosarcoma in the skull and spine, without metastatic disease. Participants must be fairly active (ECOG ≤2), have good bone marrow function, and not be pregnant. They can't join if they've had other cancers in the last two years or are on another treatment study.

Inclusion Criteria

I am 18 years old or older.

My diagnosis is either chordoma or chondrosarcoma.

I can take care of myself and perform daily activities.

+5 more

Exclusion Criteria

My cancer did not start in my brain or spinal cord.

My cancer is not melanoma, sarcoma, giant cell tumor, or aneurismal bone cyst.

I have not had any cancer other than skin or thyroid cancer in the past 2 years.

+2 more

Participant Groups

The study tests proton therapy's feasibility and immediate side effects for treating chordomas and chondrosarcomas, as well as its effectiveness and long-term side effects over time.

1Treatment groups

Experimental Treatment

Group I: Proton groupExperimental Treatment1 Intervention

Proton radiation total dose 72.00 to 79.2 Gy(RBE) in 40-44 fractions

Proton Therapy is already approved in United States, European Union, Canada, Japan for the following indications:

🇺🇸 Approved in United States as Proton Therapy for: